Insys Therapeutics reports dismissal of stockholder class action lawsuit Insys Therapeutics announced that the previously reported stockholder class action lawsuit that had been filed against the company and certain of its officers and directors in U.S. District Court for the District of Arizona was on February 20, voluntarily dismissed by the plaintiff and thereafter terminated by the court. No payment or consideration of any kind was made by any of the defendants in connection with the dismissal.
Insys Therapeutics receives FDA orphan drug designation for LEP-ETU Insys Therapeutics announced that the FDA has granted orphan drug designation to its Liposome Entrapped Paclitaxel Easy to Use, or LEP-ETU, candidate for the treatment of gastric cancer. LEP-ETU is an improved formulation of paclitaxel, a widely used chemotherapeutic agent. Insys acquired LEP-ETU during its merger in 2010 with NeoPharm.